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Abstract	
In	the	bone	marrow,	Long	Term	Haematopoietic	Stem	Cells	(LT-HSC)	are	normally	maintained	in	a	
quiescent	state.	Following	haematological	stresses,	such	as	infection,	bone	marrow	transplantation	
or	exposure	to	ionising	radiation	or	cytotoxic	drugs,	LT-HSC	are	stimulated	to	proliferate	in	order	to	
allow	repopulation	of	mature	haematopoietic	cells.		This	entry	into	the	cell	cycle	requires	changes	in	
the	metabolism	of	the	HSCs,	however	the	pathways	controlling	these	changes	are	not	fully	
understood.			In	a	recent	issue	of	Cell	Stem	Cell,	Karigane	et	al	have	shed	new	light	on	how	this	
process	is	regulated.		They	have	indentifed	a	new	role	for	the	p38	MAPK	pathway	regulating	the	
transition	of	LT-HSCs	from	a	quiescent	to	proliferative	state.		Proliferation	requires	DNA	replication	
and	thus	a	supply	of	nucleotides,	and	Karigane	have	uncovered	that	p38	regulates	purine	
metabolism	in	HSCs	via	controling	the	espression	of	key	enzymes	in	this	metabolic	pathway.	
	
	 	
Haematopoietic	stem	cells	(HSCs)	are	self-renewing	cells	that	sustain	the	production	of	all	blood	and	
immune	cell	 lineages	 throughout	 life	by	 residing	at	 the	 top	of	 the	haematopoietic	hierarchy.	They	
first	 arise	 early	 in	 embryogenesis	 and	 their	 site	 of	 action	 changes	 during	 development.	 	 In	 adult	
mammals,	 HSCs	 reside	 in	 the	 bone	marrow	within	 a	 complex	microenvironment	 termed	 the	 HSC	
niche	 (1).	 	They	are	defined	by	 their	ability	 to	completely	 repopulate	 the	entire	blood	system	of	a	
recipient,	 resulting	 in	 the	 formation	 of	 red	 blood	 cells,	 megakaryocytes,	 myeloid	 cells	 and	
lymphocytes,	 and	 in	 order	 to	 do	 this	 they	 are	 able	 to	 undergo	 asymmetric	 division	 where	 one	
daughter	 cell	 remains	 as	 a	HSC	whilst	 the	 other	 becomes	 committed	 to	 differentiation	 (2).	 In	 the	
bone	marrow,	to	prevent	exhaustion	and	to	preserve	their	ability	to	self-renew,	HSCs	are	normally	
maintained	in	a	dormant	or	quiescent	state,	from	which	they	can	be	rapidly	awakened	in	response	
to	haematological	stress	(3).		How	this	is	regulated	is	an	important	issue	and	in	a	recent	issue	of	Cell	
Stem	 Cell	 Karigane	 et	 al	 have	 shed	 new	 light	 on	 how	 the	 p38	 MAPK	 pathway	 promotes	 stress-
induced	proliferation	in	HSCs	(4).	
HSCs	 are	 maintained	 in	 quiescence	 through	 tight	 regulation	 of	 their	 metabolic	 state,	 which	 is	
controlled	by	both	cell	intrinsic	and	extrinsic	factors.	Long-term	HSCs	(LT-HSCs)	keep	rates	of	energy	
consumption	 low	 through	 anaerobic	 glycolysis,	 resulting	 in	 low	 levels	 of	 reactive	 oxygen	 species	
(ROS)	production	(5).	Maintaining	minimal	levels	of	ROS	is	thought	to	be	key	for	maintaining	the	self-
renewing	 capacity	 of	 stem	 cells	 and	 preventing	 HSC	 exhaustion	 (6).	 ROS	 production	 is	 limited	 in	
quiescent	 HSCs	 through	 the	 actions	 of	 hypoxia	 inducible	 factor	 1a	 (HIF1a),	 which	 drives	 cellular	
metabolism	towards	anaerobic	glycolysis	 instead	of	mitochondrial	 respiration	 (6,7).	HIF1a	 controls	
the	activation	of	pyruvate	dehydrogenase	kinase	2	(Pdk2)	and	Pdk4,	which	maintain	glycolysis	whilst	
actively	suppressing	mitochondrial	metabolism	in	quiescent	HSCs	(5).		
Understanding	 the	 metabolic	 changes	 that	 underlie	 the	 switch	 from	 quiescence	 to	 proliferation	
could	not	only	help	 to	 improve	the	methods	and	protocols	 for	expanding	and	maintaining	HSCs	 in	
vitro	to	prevent	HSC	exhaustion,	but	could	also	inform	on	how	alterations	in	these	cells	underlie	the	
development	of	stem	cell	diseases	such	as	leukaemias	(8).		As	quiescent	cells	have	different	energy	
requirements	 to	 active	 cells,	 changes	 in	 cellular	 metabolism	 are	 thought	 to	 be	 important	 in	 the	
transition	from	dormancy	to	cycling.	This	 is	reflected	by	the	observation	that	whilst	ROS	 levels	are	
kept	 low	 in	 quiescent	 cells,	 elevating	 ROS	 production	 promotes	 HSC	 differentiation	 to	 enable	
repopulation	(6).			
The	p38α	MAPK	pathway	has	been	suggested	to	act	downstream	of	ROS	in	HSCs	(9,10).		p38	MAPKs	
form	 a	 subgroup	of	MAPKs,	 of	which	 4	 isoforms	 exist	 in	mammalian	 cells	 and	 of	which	 p38α	has	
been	the	most	 intensely	studied.	 	 Interest	 in	p38a	 in	 immunity	was	 first	 stimulated	by	 the	 finding	
that	it	was	the	cellular	target	of	a	group	of	pyridinyl	imidazole	drugs,	such	as	SB203580,	that	could	
inhibit	 TNF	 production,	 however	 since	 then	 a	 wide	 variety	 of	 functions	 for	 p38α	 have	 been	
uncovered	 (11,12).	 	 In	 mice,	 p38a	 knockout	 is	 embryonic	 lethal	 due	 to	 problems	 with	 extra-
embryonic	 and	 placental	 development,	 impacting	 on	 cardiovascular	 development	 in	 the	 embryo	
(13,14).	 	 	Rescue	of	the	extra-embryonic	 issues	allowed	p38a	embryos	to	develop	until	term.	 	One	
knockout	 study	 additionally	 reported	 an	 issue	 with	 erythropoiesis,	 however	 this	 was	 not	 cell	
autonomous	as	HSCs	from	these	mice	could	restore	haematopoietic	development	in	recipient	mice	
(15).		Together	these	results	suggest	that	p38a	is	not	critical	for	HSC	development	and	homeostasis.			
Several	studies	have	however	indicated	roles	for	p38a	in	HSCs	following	stress.		Treatment	of	HSCs	
in	culture	with	buthione	sulfoximine	(BSO)	to	induce	ROS	production	leads	to	activation	of	p38	and	
was	 linked	 to	 a	 decreased	 ability	 to	 maintain	 HSC	 quiescence	 (9).	 	 Significantly,	 mice	 with	 null	
mutations	in	ATM,	Jak2	or	FOXO3a	show	elevated	levels	of	ROS	in	their	HSC	populations	leading	to	a	
decreased	repopulation	capacity	of	 these	HSCs	 in	adoptive	 transfer	experiments	 in	mice	 (9,10,16).		
The	 elevated	 ROS	 levels	were	 linked	 to	 increased	 p38	 activation,	 and	 long	 term	 treatment	 of	 the	
mice	with	SB203580	(which	inhibits	p38a	and	p38b)	in	vivo	was	able	to	restore	the	capacity	of	these	
HSCs	to	repopulate	the	HSC	compartment	in	lethally	irradiated	mice	(9,10).		 	To	investigate	if	p38α	
also	 played	 a	 similar	 role	 in	 wild	 type	 HSCs,	 serial	 transfer	 of	 LSK	 cells	 was	 used.	 	 In	 these	
experiments	strong	elevations	in	ROS	were	only	apparent	after	the	3rd	transfer,	and	this	correlated	
to	 increased	 to	p38α	activation	and	a	 reduction	 in	 the	capacity	of	 the	cells	 to	 repopulate	 the	HSC	
compartment	(9).	Together	these	results	suggest	that	when	HSCs	are	exposed	to	high	levels	of	ROS,	
p38α	activation	has	a	negative	effect	on	the	capacity	of	cells	to	maintain	an	HSC	phenotype.		
p38α	 is	however	activated	 in	 response	 to	many	other	 stimuli	 in	 addition	 to	ROS	and	 it	 is	possible	
that	it	may	have	different	functions	in	HSCs	depending	on	the	context	or	upstream	stimuli.		An	early	
indication	that	this	might	be	the	case	came	from	studies	on	the	p38α	activated	kinase	MK2,	where	
bone	marrow	or	LSK	cells	from	mice	deficient	in	MK2	showed	a	reduced	capacity	to	repopulate	the	
bone	marrow	 relative	 to	 wild	 type	 cells	 (17).	Work	 by	 Karigane	 et	 al	 has	 now	 uncovered	 a	 new	
mechanism	by	which	p38	MAPK	signalling	regulates	HSC	metabolism	in	response	to	haematological	
stress,	under	conditions	 that	are	unlikely	 to	be	driven	by	ROS	 (4).	 In	a	 series	of	experiments,	 they	
reveal	a	novel	p38α	dependent	pathway	that	regulates	the	metabolic	status	of	HSCs	and	promotes	
cellular	proliferation	via	activating	purine	metabolism.	 	After	 initially	 identifying	p38α	as	the	major	
p38	MAPK	 isoform	 expressed	 in	 HSCs,	 they	 analysed	 haematopoietic	 phenotypes	 in	 an	 inducible	
conditional	 p38α	 mouse	 knockout	 model.	 Global	 deletion	 of	 p38α	 induced	 by	 intra-peritoneal	
injection	of	tamoxifen	was	found	to	be	~99%	effective	in	HSCs	compared	to	wild-type	controls,	and	
under	 steady-state	 conditions	 the	 frequencies	 of	 all	 types	of	HSCs	 and	progenitors	 analysed	were	
indistinguishable	between	p38αD/D	and	p38α+/+	mice.	Importantly,	compensatory	increases	in	the	
other	p38	isoforms	was	not	observed	in	the	p38αD/D	animals.	
In	 contrast	 to	 their	 findings	 under	 steady	 state	 haematopoiesis	where	 p38α	 did	 not	 play	 a	major	
role,	p38α	was	found	to	be	important	in	the	response	of	HSCs	to	haematological	stress,	with	loss	of	
p38α	 equating	 to	 defective	 stem	 cell	 capacity.	 In	 competitive	 transfer	 of	 LSK	 cells	 into	 lethally	
irradiated	 mice,	 p38αD/D	 HSCs	 displayed	 lower	 donor-derived	 chimerism	 than	 p38α+/+	 cells,	
despite	 the	 differentiation	 status	 being	 comparable	 between	 genotypes.	 This	 difference	 was	
enhanced	 when	 a	 2nd	 serial	 repopulation	 experiment	 was	 performed.	 	 Furthermore,	 the	 stress	
resistance	 of	 p38αD/D	 mice	 in	 response	 to	 the	 chemotherapy	 drug	 5-fluorouracil	 (5-FU),	 which	
induces	 proliferation	 of	 quiescent	 HSCs	 by	 eliminating	 differentiated	 hematopoietic	 cells,	 was	
compromised	as	shown	by	a	greater	 than	50%	 increase	 in	mortality	compared	to	p38α+/+	 control	
animals.	 Importantly,	the	defective	function	of	p38αD/D	HSCs	in	response	to	haematological	stress	
was	not	attributable	to	altered	homing,	apoptosis	or	production	of	ROS.	
p38α	phosphorylation	was	found	to	be	increased	in	all	haematopoietic	cell	fractions	in	response	to	
haematological	stress	following	5-FU	injection	of	mice	and	in	transplanted	BM	cells	following	BMT.	
Analysis	of	 cell	 cycle	progression	 in	p38αD/D	HSCs	 showed	delayed	cell	division	after	BMT	and,	 in	
agreement	 with	 this,	 wild-type	 cells	 incubated	 in	 the	 presence	 of	 the	 p38	 inhibitor	 SB203580	
showed	dose-dependent	reductions	in	cell	proliferation.	Gene	set	enrichment	analysis	showed	that	
the	defects	in	cell	cycle	progression	and	proliferation	observed	in	p38αD/D	LT-HSCs	following	bone	
marrow	transplantation	were	associated	with	a	significant	reduction	in	proliferation	and	HSC-marker	
genes,	 indicating	 a	 key	 role	 for	 p38α	 in	 regulating	 cell	 cycle	 progression	 in	 HSCs	 in	 response	 to	
haematological	stress.	
In	order	for	HSCs	to	shift	from	a	quiescent	state	to	proliferation	under	homeostatic	conditions	they	
are	required	to	alter	their	metabolic	activity,	and	accordingly	the	metabolic	state	of	HSCs	has	been	
linked	 to	control	of	cell	 cycle	activity	 (5,18).	To	 investigate	potential	mechanisms	 for	 the	action	of	
p38α	 in	 regulating	 stress-induced	 metabolic	 change,	 the	 authors	 performed	 mass	 spectrometry	
based	 metabolomic	 analysis	 of	 p38αD/D	 and	 p38α+/+	 lineage	 negative,	 Sca1+,	 c-Kit-	 (LSK)	 cells	
isolated	 from	 naive	 mice	 or	 those	 that	 had	 undergone	 bone	 marrow	 transplantation.	 	 Of	 those	
metabolites	that	were	upregulated	in	transplanted	p38α+/+	LSK	cells	relative	to	cells	at	steady	state,	
most	showed	lower	levels	 in	p38α	deficient	cells.	Glycine	and	aspartic	acid	were	exceptions	to	this	
and	were	upregulated	 to	higher	 levels	 in	 transplanted	p38αD/D	 relative	 to	p38+/+	 LSK	 cells.	 Both	
Glycine	and	aspartic	 acid	 can	 feed	 into	purine	metabolism	and	 this,	 along	with	 a	 reduced	 level	of	
allantoin	 (a	 product	 of	 purine	 catabolism)	 in	 p38αD/D	 cells,	 indicated	 that	 p38α	 was	 regulating	
purine	 metabolism	 during	 stress	 haematopoiesis.	 To	 establish	 the	 mechanism	 by	 which	 p38α	
regulates	purine	metabolism	to	 induce	HSC	proliferation	 in	response	to	haematopoietic	stress,	 the	
authors	 analysed	 mRNA	 levels	 of	 enzymes	 controlling	 purine	 metabolism	 and	 found	 that	 both	
inosine-5-monophosphate	dehydrogenase	2	(Impdh2,	the	rate-limiting	enzyme	regulating	guanosine	
monophosphate	production)	and	guanosine	monophosphate	synthetase	(Gmps,	which	catalyses	the	
final	 step	 in	GMP	synthesis)	were	significantly	 reduced	 in	p38αD/D	HSCs	 relative	 to	p38α+/+	HSCs	
the	 day	 following	 transplantation.	 	 To	 provide	 further	 evidence	 for	 a	 role	 of	 p38α	 in	 purine	
metabolism	the	authors	treated	EML-C1	cells	 (a	stem	cell	 factor-dependent	 lympho-hematopoietic	
progenitor	cell	line)	with	the	p38	inhibitor	SB203580	and	showed	that	this	resulted	in	decreased	GTP	
levels.	 	Further	confirmation	of	a	role	for	Impdh	in	the	HSC	response	to	haematopoietic	stress	was	
achieved	 by	 employing	 the	 Impdh	 inhibitor	 mycophenolic	 acid	 (MPA),	 which	 dose-dependently	
blocked	the	proliferation	and	repopulation	abilities	of	HSCs.		
The	decreased	levels	of	Impdh2	and	Gmps	transcripts	in	the	p38αD/D	cells	would	be	consistent	with	
a	role	for	p38α	in	regulating	the	expression	of	these	genes,	either	directly	or	indirectly.		A	search	of	
open-access	databases	for	proteins	that	are	expressed	in	HSCs	and	which	regulate	the	transcription	
of	 purine-related	 enzymes	 revealed	 the	microphthalmia-associated	 transcription	 factor	 (Mitf)	 as	 a	
candidate	 transcription	 factor.	 Transcript	 analysis	 indicated	 that	Mitf	 expression	was	more	 highly	
expressed	 in	 HSCs	 than	 in	 differentiated	 cells,	 and	 that	 its	 expression	 in	 p38αD/D	 HSCs	 was	
significantly	 lower	 than	 in	wild-type	 cells	 following	 BMT.	 Further	 validation	 of	Mitf	 as	 a	 target	 of	
p38α	in	HSCs	was	undertaken	through	the	use	of	mice	with	the	vitiligo-associated	spontaneous	point	
mutation	 in	Mitf	 (Mitf	 vit/vit)	 that	 reduces	 its	 transcriptional	 activity.	Mitf	mutant	 cells	 displayed	
proliferation	 defects	 following	 BMT,	 along	 with	 significantly	 reduced	 expression	 of	 Gmps	 and	
Impdh2,	the	latter	of	which	was	consistently	decreased	steady	state	signifying	a	key	role	for	Mitf	in	
regulating	basal	Impdh2	expression.		The	p38α-Mitf	pathway	was	further	validated	by	demonstrating	
that	 Impdh2	 overexpression	 by	 retroviral	 transduction	 restored	 the	 short-term	 defective	
proliferation	in	p38αD/D	LSK	cells	and	Mitf	vit/vit	cells,	as	well	as	the	long-term	defects	observed	in	
Mitf	mutant	cells.	
A	 key	 question	 is	 how	 p38	 regulates	 Mitf	 transcripts	 in	 HSCs,	 as	 p38	 is	 known	 to	 regulate	 both	
transcription	 and	 mRNA	 stability.	 	 In	 melanocytes,	 p38	 has	 been	 reported	 to	 upregulate	 Mitf	
transcription	via	the	transcription	factor	CREB	(19,20).		In	line	with	this	Karigane	et	al	found	that	high	
concentrations	of	the	p38α	inhibitor	SB203580	reduced	CREB	binding	at	the	Mitf	promoter	in	EML-
C1	cells	by	approximately	50%.		These	results	do	suggest	some	interesting	questions,	including	how	
p38α	 regulates	 CREB	 in	 HSCs	 and	 if	 p38α	 also	 acts	 via	 additional	 mechanisms.	 	 While	 p38α	 can	
activate	CREB	dependent	transcription,	it	does	not	directly	phosphorylate	CREB	(21).		Instead,	p38α	
activates	the	CREB	kinases	MSK1	and	MSK2,	which	phosphorylate	CREB	on	serine	133	to	increase	its	
transcriptional	activity.		Both	MSK1	and	MSK2	are	also	activated	by	the	MAPKs	ERK1/2,	and	in	many	
systems	MSK1/2	 integrate	ERK1/2	and	p38	 inputs	 into	CREB	 (22).	 	How	 this	affects	HSCs	and	Mitf	
expression	 is	 unknown.	 	 	 Via	 the	 phosphorylation	 of	 MK2,	 p38α	 has	 well	 established	 roles	 in	
regulating	the	stability	and/or	translation	of	transcripts	containing	AU-rich	regulatory	elements	(23),	
and	given	that	MK2	has	reported	effects	on	HSC	repopulation	(17),	post-transcriptional	regulation	of	
Mitf	mRNA	by	p38α	 is	a	possibility.	 	 	While	 the	current	study	shows	that	Mitf	 transcript	 levels	are	
regulated	 downstream	 of	 p38α	 signalling,	 p38α	 may	 have	 additional	 post-translational	 roles.		
Intriguingly	Mitf	has	been	found	to	be	activated	by	p38α	in	osteoclasts	via	phosphorylation	on	serine	
307	(24)	although	the	relevance	of	this	in	HSCs	remains	to	be	determined.		
Taken	together,	 the	elegant	experiments	 reported	by	Karigane	and	co-workers	describe	a	key	 role	
for	 a	 p38α-Mitf	 pathway	 in	 regulating	 purine	 metabolism	 and	 proliferation	 in	 response	 to	
haematopoietic	stress,	and	highlight	the	importance	of	understanding	how	metabolic	changes	relate	
to	HSC	 function.	Whilst	 this	work	extends	our	knowledge	of	 the	dynamic	 roles	of	p38α	 in	HSCs,	 a	
greater	understanding	of	the	mechanisms	by	which	p38α	is	activated	in	response	to	haematological	
stress	along	with	further	details	of	exactly	how	p38α	regulates	Mitf	in	these	cells	is	likely	to	lead	to	
more	 efficient	 strategies	 to	 harness	 this	 pathway	 for	 therapeutic	 benefit.	 Given	 the	 recent	
identification	of	Mitf	as	a	novel	gene	target	regulated	by	treatment	with	the	HIV	protease	inhibitor	
nelfinavir	(25)	it	will	be	exciting	to	see	whether	modulating	Mitf	expression	is	a	viable	approach	for	
manipulating	HSCs	during	ex-vivo	expansion	or	during	leukaemia	chemotherapy.				
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